Treatment of intrahepatic cholestatic diseases
Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
1. A method of treating Alagille syndrome by administering seladelpar or a salt thereof, where the daily dose of seladelpar or a salt thereof is 5 mg, when the dose is calculated as seladelpar.
2. The method of claim 1 where the seladelpar or a salt thereof is seladelpar L-lysine dihydrate salt.
3. The method of claim 1 where the seladelpar or a salt thereof is administered orally.
4. The method of claim 2 where the seladelpar L-lysine dihydrate salt is administered orally.
5. The method of claim 1 where the seladelpar or a salt thereof is administered once/day.
6. The method of claim 2 where the seladelpar L-lysine dihydrate salt is administered once/day.
7. The method of claim 3 where the seladelpar or a salt thereof is administered once/day.
8. The method of claim 4 where the seladelpar L-lysine dihydrate salt is administered once/day.
9. A method of treating Alagille syndrome by administering seladelpar or a salt thereof, where the daily dose of seladelpar or a salt thereof is 10 mg, when the dose is calculated as seladelpar.
10. The method of claim 9 where the seladelpar or a salt thereof is seladelpar L-lysine dihydrate salt.
11. The method of claim 9 where the seladelpar or a salt thereof is administered orally.
12. The method of claim 10 where the seladelpar L-lysine dihydrate salt is administered orally.
13. The method of claim 9 where the seladelpar or a salt thereof is administered once/day.
14. The method of claim 10 where the seladelpar L-lysine dihydrate salt is administered once/day.
15. The method of claim 11 where the seladelpar or a salt thereof is administered once/day.
16. The method of claim 12 where the seladelpar L-lysine dihydrate salt is administered once/day.